Key result
Omalizumab linked to rare pulmonary vein thrombosis in a severe asthma case report.
Why the study?
Pulmonary vein thrombosis is rarely reported in association with medication use, and no cases have been reported with omalizumab treatment.
Does omalizumab treatment cause pulmonary vein thrombosis in patients with severe persistent asthma?
Case Report (n=1)
Does omalizumab treatment cause pulmonary vein thrombosis in patients with severe persistent asthma?
Answers are grounded in this paper and cite their sources.
This case highlights a potential rare adverse event of pulmonary vein thrombosis associated with omalizumab therapy.
Pulmonary vein thrombosis (PVT) is a challenging diagnosis and has been described in association with or as a complication of pulmonary tumors, lung surgeries, atrial myxoma, and after radiofrequency catheter ablation for atrial fibrillation. There are not many reported cases of PVT associated with medication use. We present a case of a 53-year-old male with a history of severe persistent asthma on omalizumab, who presented with shortness of breath and was found to have PVT on computed tomography scan of the chest. The hypercoagulable workup was normal, and the patient did not have a history of malignancy or pulmonary surgeries. Currently, available data suggest an association between omalizumab use and increased risk of arterial thrombotic events. However, on a literature search, we could not find any reported cases of PVT with omalizumab treatment.
No takes yet. Share an insight, caveat, or question.
Narukonda et al. (2017) conducted a case report in Pulmonary vein thrombosis and severe persistent asthma (n=1). Omalizumab was evaluated on Pulmonary vein thrombosis. Omalizumab treatment in a 53-year-old male with severe persistent asthma was associated with the development of pulmonary vein thrombosis, a rare complication not previously reported with this drug.
Synapse has enriched 10 related papers. Consider them for comparative context: